ArticleACS medicinal chemistry letters2016
Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors.
Article in ACS medicinal chemistry letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 65 citations in OpenAlex.
- Cross-Family Mechanistic Analysis of Plant Alkaloids Against Neglected Arboviruses and Related RNA Viruses.Molecules (Basel, Switzerland) · 2026Review
- The Antiviral Activity of Varenicline against Dengue Virus Replication during the Post-Entry Stage.Biomedicines · 2023Article
- Review
- In Vitro Anti-HIV-1 Activity of Chitosan OligomersBiotech (Basel (Switzerland)) · 2023Article
- Anti-HIV Potential of Beesioside I Derivatives as Maturation Inhibitors: Synthesis, 3D-QSAR, Molecular Docking and Molecular Dynamics Simulations.International journal of molecular sciences · 2023Article
- Lead/Drug Discovery from Natural Resources.Molecules (Basel, Switzerland) · 2022Review
- Quinolizidines as Novel SARS-CoV-2 Entry Inhibitors.International journal of molecular sciences · 2022Article
- The Key Role of Lysosomal Protease Cathepsins in Viral Infections.International journal of molecular sciences · 2022Review
- Anti-Alphaviral Alkaloids: Focus on Some Isoquinolines, Indoles and Quinolizidines.Molecules (Basel, Switzerland) · 2022Review
- Ethnobotanical Uses, Phytochemistry, Toxicology, and Pharmacological Properties ofMolecules (Basel, Switzerland) · 2022Review
- Article
- Genus Sophora: a comprehensive review on secondary chemical metabolites and their biological aspects from past achievements to future perspectives.Archives of pharmacal research · 2021Review
- Identification of anti-HIV macrocyclic daphnane orthoesters from Wikstroemia ligustrina by LC-MS analysis and phytochemical investigation.Journal of natural medicines · 2021Article
- Progress of Plant Medicine Derived Extracts and Alkaloids on Modulating Viral Infections and Inflammation.Drug design, development and therapy · 2021Review
- Design and Synthesis of Quinolizidine Derivatives as Influenza Virus and HIV-1 Inhibitors.Current medicinal chemistry · 2021Article
- Novel Betulinic Acid-Nucleoside Hybrids with Potent Anti-HIV Activity.ACS medicinal chemistry letters · 2020Article
- Rapid Recognition and Targeted Isolation of Anti-HIV Daphnane Diterpenes fromJournal of natural products · 2020Article
- Autophagy Modulation in Human Thyroid Cancer Cells following Aloperine Treatment.International journal of molecular sciences · 2019Article
- KCNQ5 activation is a unifying molecular mechanism shared by genetically and culturally diverse botanical hypotensive folk medicines.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Field-Based Affinity Optimization of a Novel Azabicyclohexane Scaffold HIV-1 Entry Inhibitor.Molecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
A quinolizidine-type alkaloid aloperine was found to inhibit HIV-1 infection by blocking HIV-1 entry. Aloperine inhibited HIV-1 envelope-mediated cell-cell fusion at low micromolar concentrations. To further improve the antiviral potency, more than 30 aloperine derivatives with a variety of N12-substitutions were synthesized. Among them, 12d with an N-(1-butyl)-4-trifluoromethoxy-benzamide side chain showed the most potent anti-HIV-1 activity with EC50 at 0.69 μM. Aloperine derivatives inhibited both X4 and R5 HIV-1 Env-mediated cell-cell fusions. In addition, both BMS-806, a compound representing a class of HIV-1 gp120-targeting small molecules in clinical trials, and resistant and sensitive HIV-1 Env-mediated cell-cell fusions were equally sensitive to aloperine derivatives. These results suggest that aloperine and its derivatives are a new class of anti-HIV-1 entry inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.